Furthermore, promising anti-tumor activity was also observed even in the fourth/ fifth-line group, with median PFS of 4.0 months and median OS of 16.3 months in the present study, indicating that PLD could be used in patients with heavily pretreated HER2-negative MBC. This evidence concerns the gene ERBB2 and neoplasm.